X4 Pharmaceuticals, Inc. (XFOR)
XFOR moved a median of -0.74% 30 minutes after news, and -1.46% by the close. How XFOR actually reacts to news — the realized, point-in-time move the market made, measured across 315 labeled events over the last three years with zero look-ahead.
XFOR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.47% | 39% | 315 |
| 30-min | -0.74% | 39% | 315 |
| 60-min | -0.74% | 43% | 315 |
| to close | -1.46% | 35% | 311 |
| Middle 50% of XFOR reactions | -3.56% to +1.86% |
|---|---|
| Median reaction (30-min) | -0.74% |
| Measured reactions | 315 |
Half of all X4 Pharmaceuticals, Inc. news events land between -3.56% and +1.86% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when XFOR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XFOR's baseline. Nothing else.
Recent XFOR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders | Press release | GlobeNewswire | +0.98% | +2.83% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | +2.83% | |
| X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures | Press release | GlobeNewswire | -0.72% | +0.72% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.05% | -1.05% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | +2.86% | |
| X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference | Press release | GlobeNewswire | -1.14% | +2.86% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | -12.38% | |
| X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting | Press release | GlobeNewswire | +0.88% | -12.38% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.22% | -1.46% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.63% | +8.92% | |
| X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +5.63% | +8.92% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.98% | +4.63% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.07% | +2.33% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.48% | |
| X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors | Press release | GlobeNewswire | -2.26% | -11.96% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.35% | -4.94% | |
| X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +1.00% | +1.26% | |
| Form EFFECT X4 Pharmaceuticals, Inc | SEC filing · Form EFFECT | SEC EDGAR | -0.25% | -7.77% | |
| Form 8-K/A X4 Pharmaceuticals, Inc For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -4.76% | |
| Form 8-K X4 Pharmaceuticals, Inc For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -2.08% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.24% | +4.04% | |
| Form S-3 X4 Pharmaceuticals, Inc | SEC filing · Form S-3 | SEC EDGAR | +0.95% | +1.66% | |
| X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.24% | +4.04% | |
| X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union | Press release | GlobeNewswire | -0.48% | -2.38% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.47% | +0.24% | |
| Form ARS X4 Pharmaceuticals, Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.84% | +3.38% | |
| Form DEF 14A X4 Pharmaceuticals, Inc For: Mar 20 | SEC filing · Form DEF | SEC EDGAR | +0.84% | +3.38% | |
| Form DEFA14A X4 Pharmaceuticals, Inc | SEC filing · Form DEFA14A | SEC EDGAR | +0.84% | +3.38% | |
| Form S-8 X4 Pharmaceuticals, Inc | SEC filing · Form S-8 | SEC EDGAR | -2.49% | -4.03% | |
| Form 10-K X4 Pharmaceuticals, Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.73% | +12.80% | |
| X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.73% | +12.80% | |
| X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference | Press release | GlobeNewswire | +1.21% | +6.06% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -3.26% | -1.19% | |
| X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome | Press release | GlobeNewswire | +0.61% | +5.85% | |
| X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +0.13% | +0.50% | |
| X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.13% | +0.50% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.34% | -4.57% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +1.34% | -4.57% | |
| X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.34% | -4.57% | |
| X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference | Press release | GlobeNewswire | +1.93% | -3.18% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | +0.27% | |
| X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million | Press release | GlobeNewswire | -4.43% | -3.54% | |
| X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering | Press release | GlobeNewswire | +25.97% | +13.43% | |
| X4 Pharmaceuticals Announces Proposed Underwritten Public Offering | Press release | GlobeNewswire | +25.97% | +13.43% | |
| Form EFFECT X4 Pharmaceuticals, Inc | SEC filing · Form EFFECT | SEC EDGAR | -1.61% | +4.52% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -3.13% | -5.00% | |
| X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation | Press release | GlobeNewswire | -3.13% | -5.00% | |
| Form S-3 X4 Pharmaceuticals, Inc | SEC filing · Form S-3 | SEC EDGAR | -0.11% | +2.48% | |
| Form S-8 X4 Pharmaceuticals, Inc | SEC filing · Form S-8 | SEC EDGAR | -0.11% | +2.48% | |
| Form 8-K X4 Pharmaceuticals, Inc For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | +4.57% | +4.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XFOR section they belong to.
Where else XFOR is measured.
XFOR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is X4 Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled XFOR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 315 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of XFOR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XFOR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.